found that overexpression of LINC DUXAP8 in hepatocellular carcinoma cells could enhance the action of SLC7A11 by promoting palmitoylation of the XC-subunit SLC7A11 and preventing its lysosomal degradation, which in turn inhibited ferroptosis and enhanced the resistance of advanced hepatocellular carcinoma cells to sorafenib (56). Here, DUXAP8 is linked to hepatocellular carcinoma.